Long-term immune-related adverse events after discontinuation of immunotherapy
| Autor: | Luc Biedermann, Karoline Horisberger, Carmen Portenkirchner, Matthias Turina, Christoph Gubler, Andreas Rickenbacher |
|---|---|
| Přispěvatelé: | University of Zurich, Horisberger, Karoline |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Male medicine.medical_specialty Time Factors medicine.medical_treatment Immunology Late onset Ipilimumab 610 Medicine & health 03 medical and health sciences 0302 clinical medicine Immune system Internal medicine Medicine Immunology and Allergy Humans 030212 general & internal medicine Colitis Adverse effect Immune Checkpoint Inhibitors Melanoma 10217 Clinic for Visceral and Transplantation Surgery 2403 Immunology business.industry Immunotherapy Middle Aged medicine.disease Discontinuation Nivolumab 030220 oncology & carcinogenesis 2723 Immunology and Allergy 2730 Oncology business medicine.drug |
| Zdroj: | Immunotherapy. 13(9) |
| ISSN: | 1750-7448 |
| Popis: | Immune checkpoint inhibitors have revolutionized the treatment of various cancers but are notorious for their potential to cause severe side effects. While most side effects occur during ongoing therapy, an increasing number of reports of late onset have emerged. It is also not yet clear how long side effects can last. Resolution is achieved under symptomatic therapy, but the side effects may persist latently. We present a patient case with recurrence of colitis after closure of an ileostomy over 1 year after discontinuation of immune checkpoint inhibitor therapy with nivolumab and ipilimumab. To the best of our knowledge, no other case with severe colitis still lasting after more than a year of suspension of therapy has yet been reported.Lay abstract Checkpoint inhibitors have revolutionized therapy for suitable cancers. However, they can cause side effects that are reminiscent of autoimmune diseases. While most adverse effects occur during ongoing therapy, there are increasing reports of late-onset adverse effects after discontinuation of therapy and of long-lasting adverse effects after discontinuation of treatment, which may remain latent even if symptom relief could be achieved by immunosuppression. We present a patient case with reappearance of a severe inflammation of the large bowel (colitis) after closure of an ostomy over 1 year after withdrawal of immune checkpoint inhibitor therapy. To the best of our knowledge, no other case with severe colitis still lasting after more than a year of suspension of therapy has yet been reported. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|